FAPI-PET imaging & theranostics: A new era in targeting cancer and fibrotic diseases
Presented by: John Babish – Ratio Therapeutics, Sherly Mosessian, PhD – SOFIE Chief Scientific Officer, […]
![Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs](https://sofie.com/wp-content/uploads/2024/12/thumbnail-small.jpg)
Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs
Jiashun Dai, Wanjing Zhou, Huaping Liu, Chengzhi Jiang, Hui Ye
![Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models](https://sofie.com/wp-content/uploads/2024/12/thumbnail-small-1.jpg)
Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models
Kaori Abe, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Sadahiro Naka, Kazuhiro Ooe, Atsushi […]
Focus on FAPI Newsletter – Summer 2024
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI […]
99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction
Cuncun Hua, Xiao-Ying Xi, Yeping Zhang, Ni Suo, Bin Tu, Ye Liu, Xiaoyan Yang, Xiaoyan […]
Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial GalleryFibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel […]
Current State of FAP Ligands for Diagnostic Use in Oncology
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
June 14, 2023 Download the Presentation […]
SOFIE and GE HealthCare SNMMI Symposium highlights FAP targeting
June 9, 2024 (Toronto, CA) – SNMMI annual meeting attendees had the opportunity to learn […]
![[68Ga]FAPI-46 Phase 2 clinical development updates](https://sofie.com/wp-content/uploads/2024/06/FAPI_Presentation2.jpg)
[68Ga]FAPI-46 Phase 2 clinical development updates
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
2024 Annual SNMMI Meeting – Toronto, Canada
June […]
Trilantic North America Completes Strategic Growth Investment in SOFIE Biosciences
NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity […]